Lung Cancer 2017: November 4, 2017 Renaissance Washington, DC Dupont Circle Hotel

Transcription

1 Lung Cancer 2017: November 4, 2017 Renaissance Dupont Circle Hotel Progress and Future Directions Course Directors: Giuseppe Giaccone, MD, PhD MedStar Georgetown Cancer Network

2 CME INFORMATION COURSE DESCRIPTION This one-day symposium will provide a comprehensive update on recent advances in the care of patients with thoracic malignancies. There is increasing recognition of a gap between evidence-based guidelines and clinical practice, with research demonstrating that up to 40% of patients fail to receive effective therapies and 20% of patients receive therapies that are ineffective or even harmful. Reducing these gaps leads to reduction in patient morbidity and mortality, and decreased health care costs. With the rapid advances in thoracic oncology, this symposium attempts to crystallize current knowledge and provide critical information and key take-home points to the busy practicing clinician involved in the care of patients with thoracic malignancies. Focus topics will include the identification of patients at high-risk for lung cancer, understanding the coming changes to lung cancer staging using the IASLC 8th edition guidelines, patient selection for multi-modality therapy in lung cancer, mesothelioma and thymomas, management of patients with a spectrum of neuro-endocrine thoracic tumors, and recent advances in immuno-oncology and targeted therapies in lung cancer. This annual one day conference will review all of the recent advances in a highly interactive case-based discussion format, supported by didactic lectures by thought leaders and other well-respected faculty in each field. LEARNING OBJECTIVES Apply the 8th edition of the IASLC staging system and utilize appropriate staging modalities to arrive at the correct stage to guide evidence-based treatment options Identify lung cancer patients who are candidates for sublobar resection or proton beam therapy Analyze different technologies and processes utilized to maximize the efficiency of molecular profiling in thoracic oncology as it pertains to CAP guidelines for optimal biopsy considerations, tissue processing and test ordering sequence, and optimal turn-around-time for results Utilize the latest evidence-based recommendations regarding utilization of biomarkers including PDL-1 testing and next generation sequencing to optimally sequence treatment options in non-small cell lung cancer Explain the evolving data pertaining to immuno-oncology in lung cancer with emphasis on appropriate sequencing with chemotherapy and the role of potential biomarkers for immunotherapy Discuss recent advances and future directions in the development of targeted therapies for lung cancer Identify patient selection for multi-modality therapies with focus on small cell lung cancer, mesothelioma and thymoma TARGET AUDIENCE This conference is intended for pulmonologists, oncologists, pathologists, nuclear medicine technologists, medical and radiation oncologists, interventional radiologists, thoracic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and medical students. CME ACCREDITATION is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CREDIT DESIGNATION designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For Nurses: For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits TM issued by organizations accredited by the ACCME. Nurses who attend a Category 1 CME certified activity can complete the continuing education hours section of the ANCC Professional Development Record in order to document the courses attended and the hours obtained.

3 FACULTY LIST COURSE DIRECTORS Director, Multidisciplinary Thoracic Oncology Clinic Full Member, Clinical & Experimental Therapeutics Program Giuseppe Giaccone, MD, PhD Director, Clinical Research MedStar Georgetown Cancer Network Associate Director, Clinical Research FACULTY Valsamo Anagnostou, MD, PhD Instructor, Oncology Upper Aerodigestive Oncology Program Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore, MD Eric D. Anderson, MD Director, Interventional Pulmonology Julie R. Brahmer, MD, MSc Director, Thoracic Oncology Program Interim Director The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Associate Professor, Oncology Johns Hopkins School of Medicine Baltimore, MD Alexander Drilon, MD Clinical Director, Early Drug Development Service Assistant Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center New York, NY Raffit Hassan, MD Co-Chief, Thoracic and Gastrointestinal Oncology Branch Senior Investigator, Head, Thoracic and Solid Tumor Immunotherapy Section National Institutes of Health Bethesda, MD Stephen V. Liu, MD Thoracic Medical Oncologist Assistant Professor, Medicine Georgetown University Medical Center Anish Thomas, MD, MBBS Staff Clinician, Developmental Therapeutics Branch National Institutes of Health Bethesda, MD Abigail Tripp Berman, MD, MSCE Associate Director, Clinical Penn Center for Precision Medicine Assistant Professor, Radiation Oncology Hospital of the University of Pennsylvania Philadelphia, PA Thomas J. Watson, MD Regional Chief, MedStar Washington Integrated Surgery Service MedStar Washington Hospital Center Professor, Surgery Georgetown University Medical Center Fred R. Hirsch, MD, PhD Chief Executive Officer International Association for the Study of Lung Cancer Associate Director University of Colorado Cancer Center Professor, Medicine and Pathology University of Colorado Denver School of Medicine Aurora, CO

4 AGENDA 7:15 AM Registration and Continental Breakfast 8:00 AM Welcome Remarks SESSION I Moderator: Eric D. Anderson, MD 8:15 AM Case Presentation 8:25 AM Updates and Changes to Lung Cancer Staging in the IASLC 8th Edition Staging System Eric D. Anderson, MD 8:45 AM Recent Updates: Lobar vs. Sublobar Resection in Lung Cancer Thomas J. Watson, MD 9:05 AM Proton Beam Radiation in Thoracic Oncology: A Niche Area or Widespread Application? Abigail Tripp Berman, MD, MSCE 9:25 AM Panel Discussion Moderator: Eric D. Anderson, MD Panelists: A. Tripp Berman, T. Watson 9:45 AM Break and Visit the Exhibits SESSION II Moderator: 10:05 AM Case Presentation 10:15 AM Harmonization of Companion Diagnostics: Vagaries of PDL 1 Testing and Other Biomarkers in Immuno-oncology Fred R. Hirsch, MD, PhD 10:35 AM Comprehensive Molecular Profiling: Expanding Therapeutic Options in NSCLCs Alexander Drilon, MD 10:55 AM Blood-Based Biomarkers Including Circulating Tumor DNA Testing in Lung Cancer Valsamo Anagnostou, MD, PhD 11:15 AM Panel Discussion Moderator: Panelists: V. Anagnostou, A. Drilon, F. Hirsch, 11:35 AM Lunch and Visit the Exhibits SESSION III Moderator: Stephen V. Liu, MD 12:35 PM Case Presentation 12:45 PM Progress and Future Directions in Small Cell Lung Cancer Anish Thomas, MD, MBBS 1:05 PM Advances in the Treatment of Thymomas and Thymic Carcinomas Giuseppe Giaccone, MD, PhD 1:25 PM Updates in the Management of Mesothelioma Raffit Hassan, MD 1:45 PM Panel Discussion Moderator: Stephen V. Liu, MD Panelists: G. Giaccone, R. Hassan, A. Thomas SESSION IV Moderator: Giuseppe Giaccone, MD, PhD 2:05 PM Case Presentation 2:15 PM Updates in Immunotherapy for Lung Cancer Stephen V. Liu, MD 2:35 PM Future of Immunotherapy in NSCLC: Combination Therapies and Future Approaches Julie R. Brahmer, MD, MSc 2:55 PM Updates on Targeted Therapies in NSCLC 3:15 PM Panel Discussion Moderator: Giuseppe Giaccone, MD, PhD Panelists: J. Brahmer, S. Liu, D. Subramaniam 3:35 PM Adjourn

5 REGISTRATION INFORMATION REGISTRATION FEES Physician $200 Resident/Fellow $35 Advanced Practice Clinician $100 Nurse $100 Allied Health Professional $100 ONLINE REGISTRATION PREFERRED Please visit our secure website at for updated program and registration information. We are unable to accept registrations or cancellations by telephone. If you wish to pay your registration fee by check, please download and print a registration form and mail it to the address on the registration form with your check. All registrations will be confirmed by only. Please use an address that you check regularly. If you have questions regarding registration or do not receive an confirmation of your registration within 1-2 business days, please contact us at medstarcme@gmail.com or CANCELLATION POLICY Cancellations made in writing by September 22, 2017 will be subject to a 50% penalty. No refunds will be given after September 22, Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs. Please call or medstarcme@gmail.com if you have any questions or need any additional information. VENUE INFORMATION RENAISSANCE WASHINGTON, DC DUPONT CIRCLE HOTEL 1143 New Hampshire Ave NW (202) SPECIAL ASSISTANCE MedStar Health wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact to notify us of your needs.

6 LUNG CANCER 2017: Progress and Future Directions November 4, 2017 Renaissance Dupont Circle Hotel FIRST NAME MIDDLE INITIAL LAST NAME SUFFIX DEGREE HOSPITAL / COMPANY / ORGANIZATION MEDICAL SPECIALTY THREE WAYS TO REGISTER: : ON THE WEB: CME.MedStarHealth.org/LungCancer BY Scan form and to: MedStarCME@gmail.com ADDRESS STREET SUITE OR APT # CITY STATE ZIP / POSTAL CODE +BY MAIL: MSH - Lung Cancer 3007 Tilden Street, NW, Suite 3N TELEPHONE FAX We are unable to accept registrations or cancellations by telephone. PAYMENT INFORMATION: Physician $200 Resident/Fellow $35 Advanced Practice Clinician $100 Nurse $100 Allied Health Professional $100 Industry $259 Check Enclosed (Please make checks payable to MSH - Lung Cancer ) Credit Card (Please indicate type below. Charges on statement will appear as CMEQT ) American Express Visa Mastercard All registrations will be confirmed by only. Please use an address that you check regularly. If you have questions regarding registration or do not receive an confirmation of your registration within 1-2 business days, please contact us at MedStarCME@gmail.com or CANCELLATION POLICY: Cancellations made in writing by September 22, 2017 will be subject to a 50% penalty. No refunds will be given after September 22, Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs. Please call or medstarcme@gmail.com if you have any questions or need any additional information. CARD NUMBER EXPIRATION DATE (MO/YEAR) *CCV NUMBER NAME OF CARDHOLDER CARDHOLDER SIGNATURE *The CCV number is a 3-digit non-raised number printed on the back of the credit card in the right hand corner of the signature strip. Amex card CCV numbers are 4-digits long and are on the front of the card. For more information, please visit: